XIAMEN, China, March 5, 2026 /PRNewswire/ — In January 2026, Xiamen C&D Inc. (stock code: 600153.SH) officially released its 2026–2030 strategic plan for its supply chain operations. Over the next five years, the company will focus on three strategic goals: improving economic efficiency, strengthening market position, and expanding overseas scale. It will also enhance five core competencies: specialization, internationalization, digitalization, foresight, and resource capabilities. Through these efforts, Xiamen C&D Inc. aims to shift from a scale-driven model toward a dual-engine growth model powered by efficiency and innovation.

According to the plan, Xiamen C&D Inc. will focus its efforts on the following five areas.:

(1) Stick to specialized operations and promote differentiated management;

(2) Accelerate its international footprint while deepening localized operations;

(3) Strengthen digital and intelligent capabilities to empower the supply chain ecosystem;

(4) Enhance endogenous foresight and optimize overall resource capabilities;

(5) Reinforce innovation-driven development and cultivate a second growth curve to inject new momentum for the company’s long-term growth.

Over the next five years, Xiamen C&D Inc. will consolidate its operations through specialization, expand growth potential  through internationalization, improve efficiency through digitalization, address cyclical challenges with internal foresight, and reinforce competitiveness through resource capabilities. By doing so, the company will strive to move from "domestically excellent" to "internationally leading" and achieve high-quality development.

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

IHS Passes Rigorous Audit for World-Wide Distribution of its Insignis™ Infusion System

Innovative Health Sciences has successfully secured the exclusive Medical Device Regulations Quality…

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of…

Growatt Achieves Global No.1 Residential PV Inverter Supplier in 2024

BERLIN, July 23, 2025 /PRNewswire/ — Growatt, a world-leading provider of distributed…